411 results match your criteria: "Inova Schar Cancer Institute[Affiliation]"

EMPROVE 24-Month Follow-Up: Judge Success by Quality of Life, Not Just Spirometry.

Ann Am Thorac Soc

February 2024

Interventional Pulmonology, Department of Surgery, Inova Schar Cancer Institute, Inova Fairfax Hospital, Falls Church, Virginia.

View Article and Find Full Text PDF

Introduction: Among uterine malignancies, endometrial cancer (EC) is the most common cancer of the female reproductive tract. Traditionally, risk stratification in EC is determined by standard clinicopathological risk factors. Although circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker in various malignancies, its clinical validity in EC remains to be established.

View Article and Find Full Text PDF

Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?

Curr Oncol Rep

January 2024

Inova Schar Cancer Institute, 8081 Innovation Park Drive, Falls Church, Falls Church, VA, 22031, USA.

Purposeof Review: This review examines the challenges of treating gastrointestinal cancer in the aging population, focusing on the importance of frailty assessment. Emphasized are the rise in gastrointestinal cancer incidence in older adults, advances in frailty assessments for patients with gastrointestinal cancer, the development of novel frailty markers, and a summary of recent trials.

Recent Findings: Increasing evidence suggests that the use of a Comprehensive Geriatric Assessment (CGA) to identify frail older adults and individualize cancer care leads to lower toxicity and improved quality of life outcomes.

View Article and Find Full Text PDF

Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough macroscopic changes in tumor volume, which limits the usability of radiological response criteria in evaluating earlier stages of disease response and necessitates much time to lapse for gross changes to be notable. One promising approach is to incorporate dynamic changes in circulating tumor DNA (ctDNA), which occur early in the course of therapy and can predict tumor responses weeks before gross size changes manifest.

View Article and Find Full Text PDF

Cryotherapy for prevention of chemotherapy induced peripheral neuropathy in breast cancer.

Crit Rev Oncol Hematol

February 2024

University of Virginia, Department of Medicine, Charlottesville, VA 22908, USA. Electronic address:

Peripheral neuropathy is a well-described complication of chemotherapy. There are no known treatments to reverse peripheral neuropathy. Chemotherapy-induced peripheral neuropathy is a dose-limiting toxicity in cancer treatment and is debilitating.

View Article and Find Full Text PDF

Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The results in a cohort of patients with solid tumors with mutations treated with cobimetinib plus vemurafenib are reported.

Methods: Eligible patients had measurable disease (RECIST v.

View Article and Find Full Text PDF

Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases. Dealing with CV disease in patients with cancer requires special knowledge beyond that included in the general core curriculum for cardiology. Therefore, the European Society of Cardiology (ESC) has developed a special core curriculum for cardio-oncology, a consensus document that defines the level of experience and knowledge required for cardiologists in this particular field.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness of a deep learning model for automatically segmenting pelvic/ovarian and omental lesions in high-grade serous ovarian cancer on CT scans.
  • Using 451 CT scans for training, evaluation, and testing, the model was compared against existing methods and trainee radiologist segmentations.
  • Results indicated that the deep learning model significantly outperformed the standard method for pelvic/ovarian lesions and performed comparably to a trainee radiologist, suggesting that automated segmentation is a viable tool in clinical settings.
View Article and Find Full Text PDF

Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable.

View Article and Find Full Text PDF

Proton pencil beam scanning craniospinal irradiation (CSI) with a single posterior brain beam: Dosimetry and efficiency.

Med Dosim

February 2024

New York Proton Center, New York, NY, USA; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

This study explores the feasibility and potential dosimetric and time efficiency benefit of proton Pencil Beam Scanning (PBS) craniospinal irradiation with a single posterior-anterior (SPA) brain field. The SPA approach was compared to our current clinical protocol using Bilateral Posterior Oblique brain fields (BPO). Ten consecutive patients were simulated in the head-first supine position on a long BOS frame and scanned using 3 mm CT slice thickness.

View Article and Find Full Text PDF

Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with mutations treated with nivolumab plus ipilimumab are reported.

Methods: Eligible patients had measurable disease (RECIST v.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers use patient-reported outcomes (PRO) to gauge patient experiences, with parents often reporting on their child's symptoms and functions in pediatric oncology.
  • Differences between how children with cancer and their caregivers assess symptoms and function can create concerns for clinicians about how to address these discrepancies with families.
  • The paper provides strategies and communication techniques for clinicians to effectively discuss the disagreement in PRO reporting to enhance family support and cohesion during the child's illness.
View Article and Find Full Text PDF

Cancer treatment-induced cardiotoxicities are an ongoing concern throughout the cancer care continuum from treatment initiation to survivorship. Several "standard-of-care" primary, secondary, and tertiary prevention strategies are available to prevent the development or further progression of cancer treatment-induced cardiotoxicities and their risk factors. Despite exercise's established benefits on the cardiovascular system, it has not been widely adopted as a nonpharmacologic cardioprotective strategy within cardio-oncology care.

View Article and Find Full Text PDF
Article Synopsis
  • The OPTIMIzE registry study examined the effectiveness of immuno-oncology therapies in advanced melanoma by comparing outcomes of patients treated with anti-PD-1 monotherapy and a combination of nivolumab and ipilimumab.
  • Patients receiving the combination therapy had a non-significantly lower risk of death and a higher disease control rate compared to those on monotherapy but experienced more severe side effects.
  • Overall, the findings suggest that immuno-oncology treatments can be beneficial for patients with advanced melanoma, balancing effectiveness with potential adverse effects.
View Article and Find Full Text PDF

 Despite advances in multimodal oncologic therapies and molecular genetics, overall survival (OS) in patients with high-grade astrocytomas remains poor. We present an illustrative case and systematic review of rare, predominantly extra-axial World Health Organization (WHO) grade 4 astrocytomas located within the cerebellopontine angle (CPA) and explore the impact of anatomic location on diagnosis, management, and outcomes.  A systematic review of adult patients with predominantly extra-axial WHO grade 4 CPA astrocytomas was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines through December 2022.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the impact of COVID-19 on female patients with breast cancer, particularly focusing on underrepresented racial/ethnic populations from March 2020 to June 2021 in the US.
  • The analysis included 1,383 patients, revealing that older age and certain racial/ethnic groups (such as Black and Asian American/Pacific Islanders) showed higher odds of severe COVID-19 outcomes.
  • Key findings noted that factors like worse performance status, pre-existing health conditions, and active cancer significantly contributed to increased severity, while variables like Hispanic ethnicity and anti-cancer therapy type did not impact outcomes as much.
View Article and Find Full Text PDF

Introduction: Axillary lymph node dissection (ALND) is recommended for patients with invasive breast cancer with axillary metastasis treated with neoadjuvant chemotherapy (NAC) who do not have a nodal pathologic complete response (n-pCR). We hypothesized that patients with a single, ultrasound-suspicious, nonpalpable lymph node (LN) at diagnosis, who do not achieve an n-pCR, will have ypN1 disease on surgical pathology.

Methods: This retrospective study identified breast cancer patients in our institution from 2012 to 2020 with axillary metastasis treated with NAC who did not achieve an n-pCR and had an ALND.

View Article and Find Full Text PDF

Background/objective: The use of patient-reported outcomes (PRO) is increasing in pediatric clinical practice and research, including in clinical trials. Treatment teams are now able to discern differences in symptom and function reports between children with cancer and their family caregivers. Few studies, however, have quantified such differences.

View Article and Find Full Text PDF

Background: Symptom burden affects quality of life and prognosis in primary brain tumor (PBT) patients. Knowing whether symptom burden varies based on sex, race, or ethnicity may affect the interpretation of the relationship between symptoms and survival may reveal issues with applying the tools to measure symptom burden to different groups and may identify inequities in symptom management that need to be addressed at a system level. To determine whether symptoms in PBT patients vary across demographic groups, we conducted a retrospective chart review of symptom burden collected as part of routine care in a diverse population.

View Article and Find Full Text PDF

Purpose: To demonstrate image-guided preplan workflows for high-dose-rate (HDR) brachytherapy for advanced gynecological malignancies.

Methods And Materials: Two different preplanning scenarios are presented: (1) CT- or MRI-based preplan with partial applicator in place; (2) Preplans generated from prior fractions. The first scenario can be applied to Syed-Neblett template-based implants or hybrid brachytherapy applicators, while the second scenario applies to hybrid applicators.

View Article and Find Full Text PDF

Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance + best supportive care (BSC) prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (advanced UC) without progression after first-line platinum-based chemotherapy.

Objective: To report post hoc analyses of subgroups defined by the duration of first-line chemotherapy and interval before maintenance.

Design, Setting, And Participants: Patients with advanced UC without progression after four to six cycles of platinum-based chemotherapy and a 4-10-wk interval after chemotherapy (n = 700) were randomized to receive avelumab + BSC or BSC alone.

View Article and Find Full Text PDF

Background: The incidence of pneumothorax after bronchoscopic lung volume reduction (BLVR) using Zephyr (Pulmonx Corporation) endobronchial valves is ~26%. Many patients who develop a postprocedural pneumothorax require chest tube placement. If a persistent airleak is present, patients tolerating waterseal can be discharged home with a mini-atrium with a low risk of empyema.

View Article and Find Full Text PDF